Overview
Aliquot publishes a restrained evidence record for this catalog identity. The page is descriptive and is not a guide to selection, dosing, administration, or treatment.
The public record is limited to regulatory status and pharmacokinetic context. Aliquot does not summarize outcomes, recommend use, or translate a label into personal advice.
Human pharmacokinetic context
8 minutes
FDA prescribing information · subcutaneous injection
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- A drug label applies to its named, FDA-approved product and labeled use; it does not validate other formulations or uses.
- A single-dose population half-life is not an individual prediction.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Egrifta SV (tesamorelin) prescribing information Regulatory status and single-dose elimination half-life.
- Aliquot compound library methodology Editorial scope and withholding rules.